Develops and commercializes treatments for gastrointestinal diseases. Focuses on vonoprazan, a potassium-competitive acid blocker (P-CAB). Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
We do not hold enough financial data on this company to point to a strength.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 30/100. For a turnaround signal, the stock first needs to close the gap with the market.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 47/100.
On our five-subject report card, PHAT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
One-line summary: few numbers, an untested story. Keep watching.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: revenue and profit, the growth trend, the balance sheet, earnings execution, the revenue breakdown.